-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that UBS released a research report saying that Yao Ming Biotech (02269.HK) reached an exclusive cooperation agreement with German medical company Fresenius to obtain developer ET rights for 37 biosimilar drugs within the next ten years. This move is seen as an affirmation of the company's R&D strength, maintaining a “buy” rating, and the target price is HK$62.

Zhitongcaijing·11/03/2026 06:33:03
Listen to the news
The Zhitong Finance App learned that UBS released a research report saying that Yao Ming Biotech (02269.HK) reached an exclusive cooperation agreement with German medical company Fresenius to obtain developer ET rights for 37 biosimilar drugs within the next ten years. This move is seen as an affirmation of the company's R&D strength, maintaining a “buy” rating, and the target price is HK$62.